Your session is about to expire
← Back to Search
Nab-paclitaxel + Gemcitabine for Pancreatic Cancer
Study Summary
This trial is testing a new combination therapy for pancreatic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My nerve damage in hands/feet is mild or none.My cancer has not spread to distant parts of my body.I am fully active or restricted in physically strenuous activity but can do light work.I do not have any serious infections needing antibiotics.My pancreatic cancer can potentially be removed by surgery.My pancreatic cancer hasn't spread far and doesn't affect major arteries or veins.My pancreatic cancer is localized and affects the area near blood vessels.My pancreatic cancer hasn't spread far and doesn't affect major arteries or veins.I have a serious heart condition or recently had a heart attack.My pancreatic cancer is confirmed and can possibly be removed with surgery.My pancreatic cancer is localized but involves major blood vessels.My pancreatic cancer cannot be removed with surgery.I have not had major surgery in the last 4 weeks.I am unable or unwilling to undergo all required study biopsies and blood tests.I am currently taking a full dose of warfarin.I haven't had treatment for other cancers in the last 5 years, except for non-melanoma skin cancer or treated cervical cancer.My blood tests show normal platelet, hemoglobin, and neutrophil levels.My liver tests are within normal limits.My cancer has not spread to distant parts of my body.I have had chemotherapy or radiation for pancreatic cancer.I am older than 18 years.I am using effective birth control methods.I have a serious stomach or intestine problem.My kidney function is within the normal range.My pancreatic cancer has spread to distant parts of my body.You have a platelet count of at least 100,000 cells/mm3.Hemoglobin > 9.0 g/dL.AST and ALT are less than 2.5 times the upper limit of normal.
- Group 1: Nab-paclitaxel and Gemcitabine for R-PDAC
- Group 2: Nab-paclitaxel and Gemcitabine for BR-PDAC
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA cleared Nab-paclitaxel and gemcitabine for use with BR-PDAC patients?
"Nab-paclitaxel and gemcitabine for BR-PDAC Patients received a safety score of 2. While there is some data indicating that the combo is safe, there are no studies yet proving its efficacy."
Are Nab-paclitaxel and gemcitabine common treatments for BR-PDAC Patients?
"At present time, there are 1165 trials being run investigating Nab-paclitaxel and gemcitabine for BR-PDAC Patients. 330 of those live clinical trials are in Phase 3. While the many studies for Nab-paclitaxel and gemcitabine for BR-PDAC Patients are based in Shanghai, China, there are 59852 locations running studies for this treatment globally."
Are patients who are over the age of 55 able to participate in this research?
"People aged 18 to 101 who meet the other eligibility requirements can apply to be in this clinical trial. There are 66 trials for people under 18 and 2282 trials for patients over 65."
Could I potentially join this clinical trial?
"This study is seeking 50 patients with adenocarcinoma that are between 18-101 years old. To be eligible, applicants must meet the following criteria: No evidence of distant metastasis representing stage IV metastatic disease., Histologically confirmed resectable or borderline resectable pancreatic adenocarcinoma., R-PDAC: No evidence of distant metastasis and tumor mass showing no extension to superior mesenteric artery (SMA) and hepatic artery. There must be a clearly defined fat plane between SMA and celiac axis. Patent superior mesenteric vein (SMV/portal"
What is the primary purpose for using Nab-paclitaxel and gemcitabine on BR-PDAC patients?
"Nab-paclitaxel and gemcitabine is a combination treatment that can be used to manage neoplasm metastasis, locally advanced non-small cell lung cancer, and metastatic bladder cancer for BR-PDAC patients."
How many participants are expected to enroll in this trial?
"Unfortunately, this particular trial is not currently looking for volunteers. Although, it's worth noting that there are 1146 other trials actively recruiting patients with adenocarcinoma and 1165 studies searching for Nab-paclitaxel and gemcitabine for BR-PDAC Patients."
Can people with the specified medical conditions participate in this trial today?
"According to the latest information found on clinicaltrials.gov, this particular trial is not currently looking for new participants. This study was originally posted on December 30th 2016 but was updated as recently as March 8th 2022. While this research is inactive at the moment, there are 2311 other clinical trials that are still enrolling patients."
In how many different locations is this trial taking place?
"The trial is currently being run by 4 different organisations including New york University, based in New York, as well as the Universities of Arizona and Colorado. Additionally, there are other sites located in 4 additional locations."
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger